Cargando…

Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?

SIMPLE SUMMARY: Exercise is associated with many aspects of a healthy lifestyle. Among these, exercise leads to the secretion of adrenaline and noradrenaline, which mobilize cells of the immune system, a process which is suggested to possess therapeutic value in cancer therapy, alone or in combinati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Agnete Witness Praest, Carnaz Simões, Ana Micaela, thor Straten, Per, Holmen Olofsson, Gitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866099/ https://www.ncbi.nlm.nih.gov/pubmed/33494360 http://dx.doi.org/10.3390/cancers13030394

Ejemplares similares

Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo
por: Holmen Olofsson, Gitte, et al.
Publicado: (2020)

Expansion With IL-15 Increases Cytotoxicity of Vγ9Vδ2 T Cells and Is Associated With Higher Levels of Cytotoxic Molecules and T-bet
por: Aehnlich, Pia, et al.
Publicado: (2020)

Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens
por: Holmen Olofsson, Gitte, et al.
Publicado: (2021)

Exploitation of gamma delta T cells in cancer immunotherapy as combined antigen-presenters and cancer cell killers
por: Holmen Olofsson, Gitte, et al.
Publicado: (2014)

Ferroptosis: friend or foe in cancer immunotherapy?
por: Demuynck, Robin, et al.
Publicado: (2023)

Interleukin-21 in cancer immunotherapy: Friend or foe?
por: Stolfi, Carmine, et al.
Publicado: (2012)

Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?
por: Yan, Cong, et al.
Publicado: (2019)

Combined killing of cancer cells and cross presentation of tumor antigen by Vγ9Vδ2 T cells
por: Olofsson, Gitte Holmen, et al.
Publicado: (2015)

β-Adrenergic Receptor Desensitization/Down-Regulation in Heart Failure: A Friend or Foe?
por: Mahmood, Abrahim, et al.
Publicado: (2022)

ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?
por: Soen, Bieke, et al.
Publicado: (2018)

Genetic engineering of T cells for increased homing to the tumor site
por: Idorn, Manja, et al.
Publicado: (2014)

Friend or Foe: Prognostic and Immunotherapy Roles of BTLA in Colorectal Cancer
por: Song, Jingjing, et al.
Publicado: (2020)

Tumor Temperature: Friend or Foe of Virus-Based Cancer Immunotherapy
por: Knapp, Jason P., et al.
Publicado: (2022)

Friend and Foe
Publicado: (1890)

Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model
por: Idorn, Manja, et al.
Publicado: (2018)

EGFR Signaling: Friend or Foe for Cartilage?
por: Qin, Ling, et al.
Publicado: (2019)

Calcium Signaling in the Thyroid: Friend and Foe
por: Asghar, Muhammad Yasir, et al.
Publicado: (2021)

Renin angiotensin system in liver diseases: Friend or foe?
por: Simões e Silva, Ana Cristina, et al.
Publicado: (2017)

Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy?
por: van Schaik, Thijs A., et al.
Publicado: (2021)

IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy
por: Romaniello, Donatella, et al.
Publicado: (2023)

B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
por: Lauss, Martin, et al.
Publicado: (2022)

Response to Wagner et al.: phosphodiesterase-2—anti-adrenergic friend or hypertrophic foe in heart disease?
por: Zoccarato, Anna, et al.
Publicado: (2016)

Phytoestrogens. Friends or foes?
por: Barrett, J
Publicado: (1996)

Polypill—Friend or Foe?
por: Rishi, Rakesh Kumar
Publicado: (2011)

Antioxidants - friend or foe?
por: Meffert, Hans
Publicado: (2008)

Inflammation: Friend and Foe
por: Kjekshus, John
Publicado: (2015)

Leukocytes: friend or foe
por: Bellingan, G
Publicado: (2000)

Viruses: Friends or foes
por: Michán, Carmen, et al.
Publicado: (2021)

Sphingolipids: Friends or Foes?
por: Hayashi, Hiroshi
Publicado: (2022)

Gabapentin—Friend or foe?
por: Russo, Marc, et al.
Publicado: (2022)

Fibronectin in Cancer: Friend or Foe
por: Lin, Tsung-Cheng, et al.
Publicado: (2019)

Chemokines and Cancer: Friends or Foes?
por: Strazza, Marianne, et al.
Publicado: (2020)

Pyroptosis in Cancer: Friend or Foe?
por: Lu, Xiuxia, et al.
Publicado: (2021)

Alcohol and Apoptosis: Friends or Foes?
por: Rodriguez, Ana, et al.
Publicado: (2015)

PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
por: Simon, Sylvain, et al.
Publicado: (2017)

Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape
por: Young, Shamar, et al.
Publicado: (2023)

Targetless T cells in cancer immunotherapy
por: thor Straten, Per, et al.
Publicado: (2016)

Reactive Oxygen Species: Friends and Foes of Signal Transduction
por: Retta, Saverio Francesco, et al.
Publicado: (2012)

PERK signaling pathway in bone metabolism: Friend or foe?
por: Guo, Jiachao, et al.
Publicado: (2021)

Signaling lymphocytic activation molecules Slam and cancers: friends or foes?
por: Fouquet, Gregory, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_88l5d1bma0ggeiqgd68coh9jlt